Daniel Stover

Daniel Stover has applied cfDNA fragmentomics to breast cancer treatment monitoring, demonstrating that genome-wide fragmentation patterns provide a cost-effective alternative to deep targeted sequencing for assessing therapy response. His work on nucleosome positioning changes during neoadjuvant chemotherapy has revealed dynamic chromatin remodeling detectable in plasma. His research on integrating fragmentomics with clinical parameters has improved prognostic models for breast cancer outcomes beyond conventional imaging and biomarker approaches.